The European Hematology Association Roadmap for European Hematology Research. A Consensus Document

Abstract The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at Euro 23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine sections in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients. Received December 15, 2015. Accepted January 27, 2016. Copyright © 2016, Ferrata Storti Foundatio

The European Hematology Association Roadmap for European Hematology Research: a consensus document

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients

"La villa de Coste Deferne, une peinture découverte au Puy-en-Velay (Haute-Loire)"

International audienceIn 2005, a series of preventive archaeological excavations on a Gallo-Roman villa was carried out in the town of Puy-en-Velay, in Auvergne, central France. We discovered, in the southern part of Anicium (the antique Puy-en-Velay),and for the first time in that area, the near complete plan of a Gallo-Roman villa built during the last third of 1st century A.D., which lasted well into 3rd and 4th centuries A.D. Several rooms of the residential part of the villa then revealed painted coatings still in place or in debris which were thoroughly analysed at the CEPMR of Soissons. Among these, we find the decor of a bottom part with a black background. Next to a rather common pattern of tufts of leaves present in the compartments, the pattern found in between with a botanical scape is rather unusual in that part of the décor. (traduction Evelyne Smith).Résumé : Une opération de fouilles archéologiques préventives d’une villa gallo-romaine a été réalisée en 2005 sur la commune du Puy-en-Velay (Haute-Loire, Auvergne). Elle a été l’occasion de mettre au jour, en périphérie méridionale de l’agglomération antique du Puy-en-Velay (Anicium), pour la première fois en territoire vellave, le plan quasi-complet d’une villa gallo-romaine implantée dans le dernier tiers du Ier s. ap. J.-C. et qui perdure pendant l’Antiquité tardive (IIIe-IVe s. ap. J.-C.). A cette occasion, plusieurs pièces de la partie résidentielle de la villa ont notamment livré des enduits peints encore en place ou au sein de niveaux de démolition qui ont fait l’objet d’une étude approfondie. Parmi elles, un ensemble nous renseigne sur le décor d’une zone inférieure à fond noir. Si les compartiments livrent un motif de touffe de feuillages assez commun, les inter-compartiments présentent un motif de hampe inédit pour cette zone du décor